Editas Medicine, Inc.
LSE: 0IFK.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Gilmore O'Neill
- Employees
- 246
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $294.4M
- Website
- https://www.editasmedicine.com
Loading 0IFK…
Loading profile data…Frequently asked questions about 0IFK
What does Editas Medicine, Inc. (0IFK.L) do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
Where does 0IFK.L trade?
Editas Medicine, Inc. (0IFK.L) trades on the London Stock Exchange.
What sector is 0IFK.L in?
Editas Medicine, Inc. (0IFK.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Editas Medicine, Inc.?
Gilmore O'Neill is the chief executive officer of Editas Medicine, Inc. (0IFK.L).
Where is Editas Medicine, Inc. headquartered?
Editas Medicine, Inc. is headquartered in United States.
Does 0IFK.L pay a dividend?
Editas Medicine, Inc. (0IFK.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0IFK.L go public?
Editas Medicine, Inc. (0IFK.L) completed its initial public offering in 2018.